Investigating long-term treatment strategies for myasthenia gravis in China
Clinical Characteristics, Prognosis and Biomarkers of Myasthenia Gravis: a Prospective Cohort Study in China
This study is testing different long-term treatment options for people with myasthenia gravis to see which works better and to find markers that show how the disease progresses.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 202 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06006832 on ClinicalTrials.gov |
What this trial studies
This observational cohort study aims to explore long-term therapeutic strategies for myasthenia gravis (MG) and identify potential biomarkers for disease progression and prognosis. Patients diagnosed with MG will be recruited and divided into two groups based on their treatment preferences: one receiving maintenance steroid therapy and the other withdrawing all immunosuppressants. The study will involve long-term follow-up assessments to evaluate the effectiveness of these strategies and the identification of biomarkers. The research is conducted at Peking Union Medical College Hospital in Beijing.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with myasthenia gravis who have been attending the outpatient department of neurology at PUMCH for at least six months.
Not a fit: Patients with comorbidities that cause skeletal muscle weakness or those without available medical records may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for myasthenia gravis, potentially reducing recurrence rates and enhancing patient outcomes.
How similar studies have performed: While there have been studies on myasthenia gravis treatment, this specific approach focusing on long-term strategies and biomarker identification is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1: Attended the outpatient department of neurology of PUMCH from 9/30/2022 to 9/30/2024. * 2: Diagnosed as myasthenia gravis. * 3: Follow-up time at PUMCH\>6 months. * 4: The patient understood and signed the informed consent form. Exclusion Criteria: * 1: Comorbidities with other conditions that cause skeletal muscle weakness make the clinical symptoms difficult to assess * 2: Records related to comorbidities and medications were not available at baseline and during follow-up.
Where this trial is running
Beijing, Beijing Municipality
- Peking Union Medical College Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Yuzhou Guan — Peking Union Medical College Hospital
- Study coordinator: Yuzhou Guan
- Email: guanyz001@163.com
- Phone: 8610-69155817
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.